Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Vanguard Total International Stock Index Fund ETF — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B), while Vanguard Total International Stock Index Fund ETF trades at $84.82 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 11.4× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| TAK | VXUS | |
|---|---|---|
Market Cap | $58.16B | $665.70B |
Volume | 2,467,530 | 4,890,695 |
Sector | Health | Sector/Thematic |
52-Week High | $19.05 | $88.41 |
52-Week Low | $13.23 | $72.17 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $86.04B | — |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VXUS, the Vanguard Total International Stock ETF, is trading at $84.78, down 1.19% on the day, with a bearish technical signal driven by moving averages. The ETF provides diversified exposure to international developed and emerging markets outside the U.S. Recent news highlights its role in portfolio diversification and long-term growth potential, with several financial firms increasing their positions in Q2 2026.
The outlook for VXUS hinges on international market performance relative to the U.S., offering a hedge against domestic downturns. Key risks include currency fluctuations, geopolitical tensions, and the ETF's inability to reclaim foreign tax credits in IRAs. Its low-cost, broad diversification presents a strategic opportunity for long-term investors seeking global equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
